baber/WOPTO huggingface dataset:
Patent FI-921682-A0 (FI)
Inventor: DE JONG JOHANNES
IPC: B66B15/04
Filed: 1992-04-14
Abstract: Traction sheave elevator consisting of a drive machine (1) and, coupled with it, a traction sheave (3) provided with a rope groove (2), the hoisting rope (4) running over the traction sheave, an elevator car (6) and its counterweight (7) suspended on the hoisting rope and moving in an elevator shaft (5), said elevator using at least two diverting pulleys (8,9) causing the hoisting rope going to the traction sheave (3) and the hoisting rope coming from the traction sheave (3) to run crosswise with respect to each other, the diverting pulleys and the traction sheave being so placed that the planes of rotation of the diverting pulleys (8,9) lie on different sides of the plane of rotation of the traction sheave (3). <IMAGE>
Patent FI-925886-A0 (FI)
Inventor: OWITI CLARICE A
IPC: D21H17/07
Filed: 1992-12-28
Abstract: A process for the felts of a papermaking operation in order to inhibit the deposition of particulate matter in the felt comprising applying to the felt a fatty acid imidazoline compound.
Patent FI-930172-A0 (FI)
Inventor: SALIN HANNU-PEKKA
IPC: H04W88/18
Filed: 1993-01-15
Abstract: PCT No. PCT/FI94/00009 Sec. 371 Date Sep. 15, 1994 Sec. 102(e) Date Sep. 15, 1994 PCT Filed Jan. 10, 1994 PCT Pub. No. WO94/16532 PCT Pub. Date Jul. 21, 1994A method and a home location register for starting a short message transmission in a mobile telephone network. To ensure that a short message is delivered successfully, a time supervision is started upon including an identity of a short message service centre in a subscriber-specific list. When a time preset in the time supervision expires, a short message transmission starting message is transmitted to each one of the short message service centres the identity of which is included in the list. The identity of the short message service centre is deleted from the list contained in the home location register. Each short message service centre transmits, in response to a short message transmission starting message, the short message to a gateway mobile exchange for the short message to be forwarded to the subscriber.
Patent FI-932650-A0 (FI)
Inventor: BANCHEREAU JACQUES
IPC: A61P37/00
Filed: 1993-06-10
Abstract: The present invention concerns pharmaceutical compositions for treating B-cell malignancies in a mammal afflicted with B-cell malignancies. More precisely, according to the invention, these pharmaceutical compositions comprise IL-4 as an active ingredient. The present invention is also directed to a method of treating B-cell malignancies, or inhibiting the proliferation or growth of malignant B-cell by administering IL-4 into mammals afflicted with B-cell malignancies. <IMAGE>
Patent FI-962094-A0 (FI)
Inventor: STEELE JOHN GERARD
IPC: A61F2/14
Filed: 1996-05-17
Abstract: PCT No. PCT/EP94/03680 Sec. 371 Date May 16, 1996 Sec. 102(e) Date May 16, 1996 PCT Filed Nov. 9, 1994 PCT Pub. No. WO95/13764 PCT Pub. Date May 26, 1995Corneal onlays for use in surgical implantation into or onto the cornea of a mammal are described. The corneal onlays according to the invention have an optical axis region with optical characteristics which provide visual acuity therethrough and are comprised of a non-biodegradable non-hydrogel ocularly biocompatible material, characterized in that the onlay has a porosity sufficient to allow passage therethrough of tissue fluid components having a molecular fluid weight greater than 10,000 daltons so as to provide for a flux of tissue fluid between cells anterior of the implanted onlay and cells posterior thereof. The porosity of the optical axis region is such that it allows the flux of tissue fluid components whilst excluding ingrowth of ocular tissue. The onlay is further characterized by being adapted for epithelial recolonization. Also described are methods for correcting the optical property of an eye or altering the appearance thereof which comprises surgically implanting into or onto the cornea a corneal onlay as described above.
Patent FI-964702-A0 (FI)
Inventor: BONDAVALLI ROLANDO
IPC: B66B13/30
Filed: 1996-11-26
Abstract: PCT No. PCT/IT94/00164 Sec. 371 Date Jan. 21, 1997 Sec. 102(e) Date Jan. 21, 1997 PCT Filed Oct. 5, 1994 PCT Pub. No. WO95/32912 PCT Pub. Date Dec. 7, 1995The invention relates to a multifunction connection and support element for an elevator door structure. The element includes, for each lateral jamb, a connection and support bracket that connects and unites each jamb with an architrave and also to an anchor bracket to be fixed to an elevator shaft wall. The anchor bracket also functions as a guide for sliding carriages of a door motion mechanism. The connection and support bracket performs all functions that in the past were carried out by several distinct connection and support elements.
Patent FI-990526-A0 (FI)
Inventor: VIALEN JUKKA
IPC: H04W48/20
Filed: 1999-03-10
Abstract: The invention is directed to a method for cell selection in a cellular telecommunication system. According to the invention, cell identification information is attached as a parameter to an RRC message initiating the state change of the mobile station to the cell-connected state. Advantageously, the network selects a cell to be suggested as the cell for use by the mobile station in the cell-connected state, and the network indicates said cell by attaching cell identification as a parameter to said RRC message. Consequently, the mobile station may make the final selection of the cell, and indicate the selected cell to the network by attaching cell identification information as a parameter to a second RRC message, such as the response message to the RRC message initiating the state change.
Patent AP-9801384-A0 (AP)
Title: Improvements of implantation rates after in vitro fertilization.
Inventor: CHWALISZ KRZYSZTOF
IPC: A61K31/4402
Filed: 1997-05-07
Abstract: A method is provided for the improvement of implantation rates and/or pregnancy rates in a female mammal, comprising administering to a female mammal in whom prganancy is desired an effective amount of: a nitric oxide synthase substrate, a nitric oxide donor, or both, optionally in combination with, (b)a progestin, and, (c)optionally, in further combination with an estrogen. A method is also provided for fertility control for a female mammal, comprising administering to a female mammal in whom pregnancy is not desired and at risk of becoming pregnant an effective amount of nitric oxide synthase inhibitor in combination with an antiprogestin. Pharmaceutical compositions are also provided
Patent IL-70684-A0 (IL)
Title: Bicyclo(4,2,0)1,3,5-octatriene derivatives,their preparation and pharmaceutical compositions containing them
IPC: C07D239/06
Filed: 1984-01-13
Abstract: Compounds of the formula:    <IMAGE>  I  in which: R1 and R2 each represent, independently of one another, hydrogen, halogen, alkyl or alkoxy having from 1 to 4 carbon atoms, sulphonamide possibly substituted by an alkyl radical having from 1 to 4 carbon atoms; or together methylenedioxy, n is 0 or 1, in racemic form or in the form of optical isomers, and also their salts of addition with pharmaceutically acceptable acids. Useful in the treatment of ailments and/or conditions which are adrenoreceptor-related, such relationship being well known in the art.
Patent AU-PN937696-A0 (AU)
Title: Casting steel strip
IPC: B22D11/06
Filed: 1996-04-19
Abstract: Method of casting steel strip in which molten steel solidifies as a shell on a chilled casting surface (100). The casting surface (100) has a texture (101) formed by a regular pattern of surface projections (103) and depressions (102) and the steel chemistry is selected to generate in the casting pool deoxidation products which form on the casting surface (100) a layer of less than 5 microns thickness a major proportion of which is liquid during cooling of the steel to below its liquidus temperature in the formation of said solidified shell. The substantially liquid layer suppresses the formation of surface defects in the solidifying metal surface due to early deposition of solid oxides on the casting surface.
Patent IL-101225-A0 (IL)
Title: Bi-and tricyclic amino alcohol esters,their preparation and pharmaceutical compositions containing them
IPC: A61P11/00
Filed: 1992-03-13
Abstract: The new compounds of formulaA-O-CO-Z(I)(wherein A and Z are defined as explained in the specification) can be prepared by conventional methods; they are suitable as active substances for pharmaceutical compositions.
Patent IL-114886-A0 (IL)
Title: Improved denture adhesive composition
IPC: A61K6/891
Filed: 1995-12-08
Abstract: A denture adhesive composition contains a denture adhesive and a pharmacologically acceptable carrier in which the denture adhesive is a salt of a copolymer of maleic acid or anhydride and a 1 to 5 carbon atom alkyl vinyl ether having a specific viscosity of at least 4.0. The denture adhesive composition is used to adhere a denture to the oral mucosa.
Patent IL-132970-A0 (IL)
Title: Partly retractable construction platform
IPC: E04G3/00
Filed: 1998-05-15
Abstract: A construction platform comprising a stationary support structure adapted to be fixedly secured to the floor of a building under construction and project from the edge of the building to a predetermined maximum extent, and a movable deck mounted on the stationary structure which may be extended as a cantilever therefrom or retracted into at least substantial registration therewith.
Patent IL-136530-A0 (IL)
Title: Waterborne polyurethanes with urea-urethane linkages
IPC: C08G18/08
Filed: 1998-12-04
Abstract: Waterborne polyurethanes possessing urea-urethane linkages that are not separated by any intervening carbon atoms may be obtained by using hydroxylamine as a chain extender. Isocyanate-terminated prepolymer possessing ionized or easily ionizable groups is reacted with NH2OH to form a polyurethane possessing urea-urethane linkages corresponding to the formula: The waterborne polyurethanes are useful in adhesive, coating and ink formulations and in the flexible package industry.
Patent IL-153515-A0 (IL)
Title: 1,3-dioxolanes with antitussive activity
IPC: A61P11/14
Filed: 2001-07-18
Abstract: (S)-3-(4-Phenyl-1-piperazinyl)-1,2-propanediol cyclic acetals useful as antitussive agents and as intermediates for the preparation of levodropropizine and the salts thereof, as well as a process for the preparation of said acetals, are disclosed.
Patent IL-154170-A0 (IL)
Title: Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
IPC: A61K33/24
Filed: 2001-08-09
Abstract: The invention discloses several novel therapeutic properties and methods of treatment using the recombinant erythropoietin prepared by expression from the Apa I restriction fragment of human genomic erythropoietin DNA transformed into baby hamster kidney cells (BHK) according to U.S. Patent No. 5,688,697 to Powell. This recombinant erythropoietin designated herein as Epoetin Omega is shown to possess several unexpected and superior qualities over other recombinant erythropoieteins such as those designated Epoetin Alfa and Beta which are prepared from genomic or cDNA expressed in Chinese Hamster Ovary (CHO) according to U.S. Patent Nos. 4,703,008 and 5,955,422 to Lin. The superior properties of Epoetin Omega include, but are not limited to, a much higher potency, a much more rapid response (i.e. no latency), longer effective serum levels, much lower antigenicity in human subjects, therapeutic activity in subjects non-responsive to the other epoetins, fewer adverse side effects such as incidents of thrombosis, reduced nausea, reduced pain at the site of injection, reduction in body pain, and most significantly, the absence of, or reduced risk of, increased blood pressure or hypertension. These novel properties provide for novel therapeutic methods including, treatment of anemia and treatment of conditions other than anemia such as fatigue or vascular pain, treatment in patients adversely effected by hypertension such as patients with heart conditions or at increased risk of thrombosis, treatment in oncology settings with and without chemotherapy or radiation therapy, and treatment with novel dosing regiments that include much lower doses and lower administration frequencies of as few as once per week or less.
Patent IL-192338-A0 (IL)
Title: NOVEL 2,4,8-TRISUBSTITUTED-8h- PYRIDO[2,3-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES
IPC: A61P31/12
Filed: 2008-06-19
Abstract: Novel substituted 2,4,8-trisubstituted -8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
Patent IL-195810-A0 (IL)
Title: A broadband switched multiplexer
Filed: 2008-12-09
Abstract: A broadband switched multiplexer comprising an input broadband demultiplexer (2) comprising a broadband input port (4) for receiving an input broadband signal and at least one output port (5) having a passband; an output broadband multiplexer (3) comprising at least two input ports (6) and a broadband output port (7), each input port having a different passband, each input port passband overlapping a different portion of the demultiplexer output port passband; the demultiplexer output port being in electrical communication with the multiplexer input ports by signal paths (8), each signal path having a switch (13) for opening and closing the path therein.
Patent IL-220128-A0 (IL)
Title: Method for the humanization of antibodies and humanized antibodies thereby obtained
IPC: C07K16/22
Filed: 2012-06-03
Abstract: A humanized anti-NGF antibody having one or more complementary determining regions (CDRs) selected from a heavy chain first CDR comprising the amino acid sequence GFSLTNNNVNW, a heavy chain second CDR comprising the amino acid sequence GVWAGGATDYNSALKS, a heavy chain third CDR comprising the amino acid sequence DGGYSSSTLYAMDA, a light chain first CDR comprising the amino acid sequence RASEDIYNALA, a light chain second CDR comprising the amino acid sequence HT and a light chain third CDR sequence comprising the amino acid sequence QHYFHYPRT.
Patent RO-134545-A0 (RO)
Title: Disinfection cabin with uv-c lamps
Inventor: MACARIE VASILE
IPC: A61L2/10
Filed: 2020-05-07
Abstract: The invention relates to a disinfection cabin with UV-C lamps, meant to be used for disinfecting the uniform/equipment and footwear of the person wearing them. According to the invention, the cabin is provided with an adjustable protection system for hands and face and consists of a steel frame closed with painted sheet metal at the top and lateral sides and with semi-transparent plexiglass at the back side, inside the cabin there being provided eight UV-C neon lamps of 11W with a wavelength of 254.5 nm and three UV-C neon lamps of 7W with a wavelength of 254.5 nm, inside the cabin there being also provided an octagon sliding vertically up and down, which comprises six UV-C lamps of 11W with a power of 3.2W, and two sole-shaped slots being cut-out in the cabin metal floor for disinfecting the footwear, each slot having one lamp of 11W with a power of 3.2W mounted therein.
Patent RO-137329-A0 (RO)
Title: Collagen nanothreads from donkey skin and process for preparing the same
Inventor: RÂPĂ MARIA
IPC: A61L27/24
Filed: 2022-11-28
Abstract: The invention relates to a composition for making nanothreads based on collagen from donkey skin and to a process for preparing them, the nanothreads being meant to be used to produce non-active medical dressings. The claimed composition comprises the following elements, expressed as percentage by weight: 12% collagen or collagen-keratin mixture and 88% acetic acid solution in water, at an acetic acid to water volume ratio of 9 :1. The claimed process consists in preparing a working solution from the above elements, by stirring for 6 hours, at room temperature, at a speed of 600 rpm, said solution is introduced into a syringe fixed in a pump, then the solution is electrospun with a flow rate of between 0.6...0.8 mL/h, having as a spinneret a stainless steel tipless needle, with an inner diameter of 0.168 mm, which is connected to a high voltage source ranging between 22.71...25.59 kV, with the distance between the end of the needle and the collector of 9...14 cm, resulting in nanothreads with variable diameters ranging between 73.15...133.33 nm.
Patent AP-2004002978-A0 (AP)
Title: Annulus monitoring system
Inventor: LAUREANO MARCIO PCHEK
IPC: E21B33/047
Filed: 2002-08-19
Abstract: Apparatus and a system for accessing one or more of the annuli defined between casing strings in a subsea wellhead that are usually sealed for the production stage of the well. Access to an annulus (30) is made via the wall of the wellhead housing (12) at a location where is communicates with the annulus. The access is a passageway (31) having a first opening in communication with the annulus and a second opening either at the external surface of the wall or at a location on the inner surface of the wall above the casing hangar seal for the inner casing (14), which is not in communication with the annulus apart from the passageway. An isolation valve (32) communicates with the passageway and with apparatus for monitoring or controlling pressure of flow in the annulus. The passageway may be used with an open lower end to the annulus during drilling stages for material transfer and during production stage to monitor/control a sealed annulus.
Patent LU-88724-A1 (LU)
Title: Prodn. of quinolone-contg. tablets for oral use - avoids formation of slow dissolving hydrate(s) and problems with cleavage
Inventor: GOUSSET GABRIEL
IPC: A61K31/4709
Filed: 1996-03-14
Abstract: Oral formulations containing quinolones are prepared by compacting, grinding, then compressing the mixture of active material and excipients. Pref. quinolone is a cpd. of formula (I) or its salt. R1 = 1-4C alkyl, fluoroethyl, cyclopropyl, methylamino, or difluoro phenyl, X = N or C(R7); R7=H, Cl, F; or R1+R7 complete a 6-membered heterocycle (which is substituted by methyl and may contain O or S); R2 = H; or when R7 = F, then R2 may also be NH2; R3 = H, 2,8-diazabicyclo[4.3.0]non-8-yl or a gp of formula (i) or (ii); R4, R5, and R6 = H or methyl.
Patent MA-23131-A1 (MA)
IPC: A23N12/02
Filed: 1994-03-09
Abstract: The subject of the invention is an apparatus for washing beet which is made up of an elongate rotary drum with a perforated wall and is fitted on the inside with screw conveyors or blades which carry the beet from one end to the other, and with sprinkler pipes having nozzles which spray water under pressure onto the beet. With a view to using an apparatus of this type for the final washing of beet in the washing station of a sugar refinery, and providing better cleaning of the sugar-containing grooves than is obtained with conventional apparatuses, the drum has on its inside surface low humps (48) and the dimensions of the apparatus and its method of operating are chosen to ensure that the beet (26) is conveyed in a single layer. <IMAGE>
Patent MA-27074-A1 (MA)
Title: 2-amino-6(phenyl-2,4,5-substitue)-pyridines destinées a etre utilisees comme inhibiteurs de l'oxyde nitrique-synthase
Inventor: JOHN ADAMS LOWE III
IPC: A61K31/44
Filed: 2004-04-08
Abstract: DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 10 Octobre 2001 60/328,253 Voir en annexe le titre de l'invention et le texte de l'abrégé 2-amino-6(phényl 2,4,5-substitué)-pyridines destinées à être utilisées comme inhibiteurs de l'oxyde nitrique-synthase La présente invention concerne les composés consistant en 6-[4-(N-méthyl-3-azétidinoxy)-5-éthyl-2-méthoxyphényl]-pyridine-2-ylamine, 6-[4-(N,N-diméthylaminométhyl)-5-éthyl-2-méthoxyphényl]-pyridine-2-ylamine, 6-[4-(N-méthylaminométhyl)-5-éthyl-2-méthoxyphényl]-pyridine-2-ylamine, 6-[4-(3-azétidinoxy)-5-éthyl-2-méthoxyphényl]-pyridine-2-ylamine et 6-[4-(2-diméthylaminoéthoxy)-5-éthyl-2-méthoxyphényl]-pyridine-2-ylamine et leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques contenant ces composés et l'utilisation de ces composés comme inhibiteurs de l'oxyde nitrique-synthase dans le traitement et la prévention de troubles du système nerveux central et d'autres troubles.
Patent MA-20150199-A1 (MA)
Inventor: ABDELLATIF BENABDELLAH
IPC: E06B7/36
Filed: 2013-11-26
Abstract: قدم هذا الإختراع حلا للحماية الأصابيع و ذلك عند فتح أو غلق أبواب العربة و يتعلق الأمر بنظام يعتمد في إشتغاله على خلايا ضوئية يتم دمجها في مساحة مستوية مطبقة على حواف هيكل باب العربة
Patent UY-25522-A1 (UY)
Title: Método y sistema para expandir la capacidad de datos de un canal de control de red celular.
Inventor: JERE T SANDIDGE
IPC: H04M11/00
Filed: 1999-05-21
Abstract: Sistema de radiotelefonía celular móvil (CMR) que posee una serie de células para comunicarse con radioteléfonos celulares móviles dentro de áreas de cobertura de la serie de células, un sistema de mensaje de datos para comunicar un mensaje de control, el cual comprende: un centro de comunicación móvil (MSC) para comunicar el mensaje de control a través de un canal de control de avance del sistema CMR, cuando dicho mensaje de control contiene un identificador de operación que define una operación seleccionada entre una pluralidad de operaciones; y una pluralidad de dispositivos de reporte de datos, cada uno de los cuales responde a la recepción de un mensaje de control para realizar la operación definida por el identificador de operación, la cual puede ser realizada por cada uno de los dispositivos de reporte de datos. Más específicamente, se refiere la expansión de la capacidad efectiva de datos de un canal de control de red celular. Se incluye también un método que comprende: recibir un pedido de operación de un proveedor de servicio de datos, traducir el pedido de operación en un identificador de operación, transmitir el identificador de operación al MSC, convertir el identificador de operación en un formato adecuado para su transmisión a por lo menos uno de los dispositivos de reporte de datos a través del canal de control de avance.
Patent UY-26176-A1 (UY)
Title: Formas polimorfas de un citrato de azobiciclo (2,2,2) octan- 3-amina y sus composiciones farmacéuticas.
Inventor: WINT MICHAEL JAMES CASTALDI GE
IPC: A61K31/439
Filed: 2000-05-29
Abstract: Una forma polimorfa cristalina individual del citrato de (2S, 3S)-N- (metoxi-5-t-butilfenilmetil-2,difenilmetil-1-azobiciclo(2,2,2) octan-3-amina (citrato monohidrato) y su composición farmacéutica. La composición farmacéutica de la forma polimorfa si el citrato monohidrato tiene la estabilidad necesaria para una formulación para tratar la émesis. La administración de esta composición farmacéutica es una forma de dosificación oral de liberación inmediata, preferiblemente en forma de comprimido o cápsula, o intravenosa.